Jounce Therapeutics Added to NASDAQ Biotechnology Index
December 14 2017 - 7:00AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that it has been selected for addition to the
NASDAQ Biotechnology Index®. The addition will take effect prior to
the open of the U.S. markets on Monday, December 18, 2017.
The NASDAQ Biotechnology Index (NBI) contains
securities of NASDAQ-listed companies classified according to the
Industry Classification Benchmark as either Biotechnology or
Pharmaceuticals. Companies in the NBI must meet eligibility
requirements, including minimum market capitalization and average
daily trading volume, among other criteria. The NASDAQ
Biotechnology Index is re-ranked annually and forms the basis for a
number of Exchange Traded Funds (ETFs), including the iShares
NASDAQ Biotechnology ETF. For more information about the NASDAQ
Biotechnology Index visit
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Jounce TherapeuticsJounce
Therapeutics, Inc. is a clinical stage immunotherapy company
dedicated to transforming the treatment of cancer by developing
therapies that enable the immune system to attack tumors and
provide long‑lasting benefits to patients. Through the use of its
Translational Science Platform, Jounce first focuses on specific
cell types within tumors to prioritize targets, and then identifies
related biomarkers designed to match the right immunotherapy to the
right patient. Jounce’s lead product candidate, JTX-2011, is a
monoclonal antibody that binds to and activates ICOS and is
currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For
more information, please visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Katie EnglemanPure
Communications, Inc.(910) 509-3977
kengleman@purecommunications.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024